A Phase 3 interventional study of somatropin and placebo in Chronic Kidney Disease and End-Stage Renal Disease, sponsored by Novo Nordisk A/S. Terminated at 381 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-07.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 48th largest by enrollment of the 638 interventional ones that give a count, is one of 36 that started in 2007, is one of 76 in phase 3, and was the 106th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 36 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 712 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 611 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 4 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania.
The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.
The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
This study's enrollment of 712 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Somatropin once daily from week 0 to end of trial
Drug: somatropin
Placebo once daily to end of trial
Drug: placebo
20 mcg/kg/day, injected s.c. (under the skin)
Placebo injected s.c (under the skin)
Mortality - Time to All-cause Death
Time to all-cause death. Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants dead estimated using Kaplan-Meier. Summary data illustrates mortality until 52 weeks, because very few subjects had trial time longer than 52 weeks. Due to early trial termination, median trial time was 17.4 weeks.
Time frame: week 0, trial termination
Morbidity - Time From Randomisation to Next Cardiovascular Event (Defined as Composite of All-cause Mortality, Non-fatal Myocardial Infarction, Stroke, Cardiac Insufficiency and Other Thrombo-embolic Event)
Morbidity - time from week 0 to next cardiovascular event (composite of all-cause mortality and cardiovascular events defined as adjudicated medical event of special interest and categorised as myocardial infarctions, cardiac insufficiencies, strokes or other thrombo-embolic events). Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants with events estimated using Kaplan-Meier. Summary data illustrates morbidity until 52 weeks, because very few subjects had trial time longer than 52 weeks.
Time frame: week 0, trial termination
Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures
The number of times that the patient was hospitalised in addition to hospitalisation for normal dialysis procedures measured from week 0 (randomisation) to the time the trial was terminated.
Time frame: week 0, trial termination
Mortality - Two-year Mortality Rate
Time frame: week 0, trial termination
Health Related Quality of Life Assessments
Summary from activity of daily living from the Rotterdam Symptom Checklist (RSCL) measuring activity from 1 (active) to 5 (inactive). The Edmonton Symptom Assessment System (ESAS), subjects assess their health in the last 24 hours on a scale from 1 (good health) to 3 (feeling poorly). The EQ-5D is a measure of subjects' health outcome from 0 (death) to 1 (full health). SF-36 (Short Form (36)) covering mental and physicial health is provided in a scale from 0-100 with higher scores indicating greater satisfaction.
Time frame: week 0, trial termination
A total of 202 sites in 17 countries: United States, Canada, United Kingdom, Sweden, Denmark, France, Germany, Poland, Hungary, Spain, Portugal, Turkey, Israel, Argentina, Brazil, Russia, South Africa. Italy planned to participate but never randomised any subjects.
| Milestone | Somatropin | Placebo |
|---|---|---|
| Started | 357 | 355 |
| Exposed to trial drug | 346 | 349 |
| Completed | 0 | 0 |
| Not completed | 357 | 355 |
| Withdrew: Protocol violation | 5 | 6 |
| Withdrew: Adverse event | 52 | 41 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 3 | 4 |
| Withdrew: Trial terminated | 216 | 253 |
| Withdrew: End hemodialysis due to renal transplant | 10 | 4 |
| Withdrew: Pregnancy/intention to become pregnant | 1 | 0 |
| Withdrew: Any condition in exclusion criteria | 4 | 6 |
| Withdrew: Switch to peritoneal or home dialysis | 2 | 2 |
| Withdrew: Move to nonparticipating dialysis center | 2 | 1 |
| Withdrew: Critically ill | 2 | 0 |
| Withdrew: Unclassified | 48 | 32 |
| Withdrew: Not exposed to trial drug | 11 | 6 |
Time to all-cause death. Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants dead estimated using Kaplan-Meier. Summary data illustrates mortality until 52 weeks, because very few subjects had trial time longer than 52 weeks. Due to early trial termination, median trial time was 17.4 weeks.
| percentage of participants | Somatropin | Placebo |
|---|---|---|
| Baseline (week 0) | 0 ± NA | 0 ± NA |
| Week 26 | 8 | 8 |
| Week 44 | 13 | 17 |
| Week 52 | 29 | 23 |
Morbidity - time from week 0 to next cardiovascular event (composite of all-cause mortality and cardiovascular events defined as adjudicated medical event of special interest and categorised as myocardial infarctions, cardiac insufficiencies, strokes or other thrombo-embolic events). Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants with events estimated using Kaplan-Meier. Summary data illustrates morbidity until 52 weeks, because very few subjects had trial time longer than 52 weeks.
| percentage of participants | Somatropin | Placebo |
|---|---|---|
| Baseline (week 0) | 0 ± 0 | 0 ± 0 |
| Week 26 | 12 | 17 |
| Week 40 | 18 | 23 |
| Week 52 | 31 | 24 |
The number of times that the patient was hospitalised in addition to hospitalisation for normal dialysis procedures measured from week 0 (randomisation) to the time the trial was terminated.
| hospitalisations | Somatropin | Placebo |
|---|---|---|
| Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures | 0.5 ± 0.9 | 0.5 ± 1.0 |
No measurements were reported for this outcome.
Summary from activity of daily living from the Rotterdam Symptom Checklist (RSCL) measuring activity from 1 (active) to 5 (inactive). The Edmonton Symptom Assessment System (ESAS), subjects assess their health in the last 24 hours on a scale from 1 (good health) to 3 (feeling poorly). The EQ-5D is a measure of subjects' health outcome from 0 (death) to 1 (full health). SF-36 (Short Form (36)) covering mental and physicial health is provided in a scale from 0-100 with higher scores indicating greater satisfaction.
| scores on a scale | Somatropin | Placebo |
|---|---|---|
| RSCL (overall mean), N= 316, 312 | 2.9 ± 0.9 | 3.0 ± 0.9 |
| ESAS (overall mean), N= 309, 313 | 3.0 ± 1.9 | 3.0 ± 2.0 |
| EQ-5D (UK overall score), N= 305, 299 | 0.596 ± 0.310 | 0.597 ± 0.321 |
| SF-36 (overall physical health), N= 318, 315 | 48 ± 22 | 49 ± 22 |
| SF-36 (overall mental health), N= 318, 315 | 61 ± 21 | 62 ± 21 |
Collected over The adverse events were collected from July 2007 to January 2009.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Somatropin | — | 122/346 (35.3%) | 225/346 (65%) |
| Placebo | — | 136/349 (39%) | 264/349 (75.6%) |
| Event | Somatropin | Placebo |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 7/346 | 12/349 |
| PneumoniaInfections and infestations | 10/346 | 8/349 |
| Myocardial infarctionCardiac disorders | 4/346 | 9/349 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 5/346 | 9/349 |
| Cardiac arrestCardiac disorders | 2/346 | 8/349 |
| Atrial fibrillationCardiac disorders | 7/346 | 5/349 |
| SepsisInfections and infestations | 2/346 | 7/349 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/346 | 7/349 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 5/346 | 7/349 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/346 | 7/349 |
| Event | Somatropin | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 29/346 | 36/349 |
| DiarrhoeaGastrointestinal disorders | 23/346 | 36/349 |
| VomitingGastrointestinal disorders | 17/346 | 29/349 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 25/346 | 19/349 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/346 | 25/349 |
| HypotensionVascular disorders | 24/346 | 23/349 |
| HeadacheNervous system disorders | 23/346 | 22/349 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 22/346 | 22/349 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/346 | 22/349 |
| AstheniaGeneral disorders | 9/346 | 19/349 |
| Age, Continuous(years) | Somatropin | Placebo | Total |
|---|---|---|---|
| Mean | 62.2 ± 13.5 | 61.0 ± 14.2 | 61.6 ± 13.8 |
| Sex: Female, Male(Participants) | Somatropin | Placebo | Total |
|---|---|---|---|
| Female | 175 | 139 | 314 |
| Male | 171 | 210 | 381 |
| Ethnicity (NIH/OMB)(Participants) | Somatropin | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 55 | 66 | 121 |
| Not Hispanic or Latino | 286 | 279 | 565 |
| Unknown or Not Reported | 5 | 4 | 9 |
| Race (NIH/OMB)(Participants) | Somatropin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 8 | 4 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 114 | 113 | 227 |
| White | 205 | 213 | 418 |
| More than one race | 14 | 17 | 31 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Diabetes(participants) | Somatropin | Placebo | Total |
|---|---|---|---|
| Type 1 diabetes mellitus | 12 | 16 | 28 |
| Type 2 diabetes mellitus | 161 | 150 | 311 |
| Not Diabetic | 173 | 183 | 356 |
| BMI(kg/m2) | Somatropin | Placebo | Total |
|---|---|---|---|
| Mean | 28.9 ± 8.6 | 28.4 ± 8.0 | 28.7 ± 8.3 |
| Duration of Diabetes(years) | Somatropin | Placebo | Total |
|---|---|---|---|
| Median | 17.5 (1.6 to 63.6) | 20.3 (1.2 to 58.5) | 18.4 (1.2 to 63.6) |
| Duration of Dialysis(years) | Somatropin | Placebo | Total |
|---|---|---|---|
| Median | 2.9 (0.2 to 27.1) | 2.9 (0.3 to 34.6) | 2.9 (0.2 to 34.6) |
2 further baseline measures are reported on the registry.
Showing the first 100 of 381 sites across 21 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone